St. Louis School of Medicine: Promising Role for Whole Genome Sequencing in Guiding Blood Cancer Treatment
March 11, 2021
March 11, 2021
ST. LOUIS, Missouri, March 11 (TNSJou) -- The Washington University St. Louis School of Medicine issued the following news release:
For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes. Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three deca . . .
For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes. Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three deca . . .